Pharmabiz
 

US FDA clearance for Abbott's new test to detect vitamin D levels

Abbott Park, IllinoisFriday, December 2, 2011, 11:00 Hrs  [IST]

The US Food and Drug Administration (FDA) has cleared Abbott's for a fully-automated 25-OH vitamin D assay performed on its widely used Architect laboratory testing platform.

Published data from the Third National Health and Nutrition Survey, reported in the Archives of Internal Medicine, show that less than a quarter of Americans have the minimal vitamin D levels necessary for general health benefits. There are a number of factors that may contribute to people having low vitamin D, including low dietary intake, sun avoidance, geographic location, age and ethnicity.

Low vitamin D can cause skeletal disorders, such as rickets in children and bone loss in adults, and has been linked to an increased risk of hip fractures. Although research is still being conducted in this area, some studies have shown that people with a low level of vitamin D may have elevated risk for cardiovascular problems, autoimmune disorders and some infectious diseases.

"As health care professionals and patients become aware of the potential health risks associated with low vitamin D, labs have seen a surge in test orders," said Brian Blaser, senior vice president, Diagnostics, Abbott. "The new Architect 25-OH Vitamin D assay has shown excellent precision and offers a fully-automated solution that may help laboratories cope with escalating demand for vitamin D testing and help get results to physicians and their patients much sooner."

With a simple blood test, the Architect 25-OH Vitamin D assay can measure the stable form of vitamin D, 25-hydroxyvitamin D (25-OH vitamin D), the body’s repository of vitamin D. In the kidneys, 25-OH vitamin D converts into the active form of the vitamin that helps regulate calcium and phosphate levels. 25-OH vitamin D is established as the appropriate measurable indicator of vitamin D status because it is stable and easily measured.

"Regular vitamin D testing can be important for people who may have risk factors that could contribute to vitamin D deficiencies," said Beth Schodin, Ph.D, scientific affairs manager, Diagnostics, Abbott. "The availability of a highly accurate and reliable vitamin D assay can give physicians timely information about their patients and help them identify appropriate treatment options."
Intended Use and Important Safety Information:

The Architect family of analyzers includes the i1000 SR and i2000 SR for immunoassay testing, the c4000, c8000, and c16000 for clinical chemistry testing, and the ci4100, ci8200, and ci16200 integrated immunoassay/chemistry systems. Abbott's unique technologies include the Robotic Sample Handler to prioritize emergency tests; sample clot and bubble detection to verify sampling integrity; and FlexRate and Chemiflex assay technologies. Architect systems use identical easy-to-use software and common reagents across all members of the family.  

Abbott is a global leader in in vitro diagnostics and offers a broad range of innovative instrument systems and tests for hospitals, reference labs, molecular labs, blood banks, physician offices and clinics.

 
[Close]